Matches in SemOpenAlex for { <https://semopenalex.org/work/W2027837557> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W2027837557 endingPage "17" @default.
- W2027837557 startingPage "12" @default.
- W2027837557 abstract "Until recently, the prognosis of patients with deep primary melanomas or regionally metastatic nodal disease has been poor, with 5-year survival rates of 25–50%. The results of the Eastern Cooperative Oncology Group (ECOG) trial 1684 represent the first evidence of effective adjuvant therapy for these patients. Interferon alfa-2b (IFN-α2b) administered at maximally tolerated doses for 1 year significantly improved both relapse-free and overall survival. The impact of interferon therapy was observed early during treatment and the effect was durable. The results of this trial represent a breakthrough in the treatment of high-risk resected cutaneous melanoma and identify the new reference standard for new cytokines, vaccines and combinations. The favourable results provide a strong impetus for redoubled research into immunotherapy for treatment of melanoma. Specifically, ganglioside vaccines have been identified that induce antibody responses and may affect patient outcome and peptide/protein vaccines that are recognised by the T-cell have been identified in large numbers. ECOG and the U.S. Intergroup are conducting a phase III trial (E1694) that compares GM2 vaccine to IFN-α2b and a phase II trial evaluating concurrent or sequential use of interferon and vaccines for patients with resectable melanoma. They are also planning phase II trials of peptides for patients with metastatic unresectable melanoma. Laboratory analyses of the immune responses induced by IFN and the several vaccines are anticipated to reveal the fundamental immune mechanisms that are important for relapse-free survival and immunological control of melanoma." @default.
- W2027837557 created "2016-06-24" @default.
- W2027837557 creator A5007239425 @default.
- W2027837557 date "1998-04-01" @default.
- W2027837557 modified "2023-10-16" @default.
- W2027837557 title "Systemic adjuvant treatment of high-risk melanoma: the role of interferon Alfa-2b and other immunotherapies" @default.
- W2027837557 cites W1561157384 @default.
- W2027837557 cites W1828940258 @default.
- W2027837557 cites W1866549327 @default.
- W2027837557 cites W1929485758 @default.
- W2027837557 cites W1985366163 @default.
- W2027837557 cites W2004486693 @default.
- W2027837557 cites W2019726352 @default.
- W2027837557 cites W2025851036 @default.
- W2027837557 cites W2035523519 @default.
- W2027837557 cites W2047181127 @default.
- W2027837557 cites W2049525098 @default.
- W2027837557 cites W2076171175 @default.
- W2027837557 cites W2083574998 @default.
- W2027837557 cites W2147103876 @default.
- W2027837557 cites W2231116265 @default.
- W2027837557 doi "https://doi.org/10.1016/s0959-8049(97)10159-9" @default.
- W2027837557 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9849403" @default.
- W2027837557 hasPublicationYear "1998" @default.
- W2027837557 type Work @default.
- W2027837557 sameAs 2027837557 @default.
- W2027837557 citedByCount "33" @default.
- W2027837557 countsByYear W20278375572013 @default.
- W2027837557 countsByYear W20278375572015 @default.
- W2027837557 countsByYear W20278375572017 @default.
- W2027837557 countsByYear W20278375572020 @default.
- W2027837557 crossrefType "journal-article" @default.
- W2027837557 hasAuthorship W2027837557A5007239425 @default.
- W2027837557 hasConcept C126322002 @default.
- W2027837557 hasConcept C143998085 @default.
- W2027837557 hasConcept C203014093 @default.
- W2027837557 hasConcept C2776178377 @default.
- W2027837557 hasConcept C2776694085 @default.
- W2027837557 hasConcept C2777658100 @default.
- W2027837557 hasConcept C2777701055 @default.
- W2027837557 hasConcept C2777863537 @default.
- W2027837557 hasConcept C2777982462 @default.
- W2027837557 hasConcept C2781228144 @default.
- W2027837557 hasConcept C2909179924 @default.
- W2027837557 hasConcept C502942594 @default.
- W2027837557 hasConcept C535046627 @default.
- W2027837557 hasConcept C71924100 @default.
- W2027837557 hasConcept C8891405 @default.
- W2027837557 hasConceptScore W2027837557C126322002 @default.
- W2027837557 hasConceptScore W2027837557C143998085 @default.
- W2027837557 hasConceptScore W2027837557C203014093 @default.
- W2027837557 hasConceptScore W2027837557C2776178377 @default.
- W2027837557 hasConceptScore W2027837557C2776694085 @default.
- W2027837557 hasConceptScore W2027837557C2777658100 @default.
- W2027837557 hasConceptScore W2027837557C2777701055 @default.
- W2027837557 hasConceptScore W2027837557C2777863537 @default.
- W2027837557 hasConceptScore W2027837557C2777982462 @default.
- W2027837557 hasConceptScore W2027837557C2781228144 @default.
- W2027837557 hasConceptScore W2027837557C2909179924 @default.
- W2027837557 hasConceptScore W2027837557C502942594 @default.
- W2027837557 hasConceptScore W2027837557C535046627 @default.
- W2027837557 hasConceptScore W2027837557C71924100 @default.
- W2027837557 hasConceptScore W2027837557C8891405 @default.
- W2027837557 hasLocation W20278375571 @default.
- W2027837557 hasLocation W20278375572 @default.
- W2027837557 hasOpenAccess W2027837557 @default.
- W2027837557 hasPrimaryLocation W20278375571 @default.
- W2027837557 hasRelatedWork W2014374827 @default.
- W2027837557 hasRelatedWork W2018670987 @default.
- W2027837557 hasRelatedWork W2052392525 @default.
- W2027837557 hasRelatedWork W2079002457 @default.
- W2027837557 hasRelatedWork W2090324800 @default.
- W2027837557 hasRelatedWork W2152169833 @default.
- W2027837557 hasRelatedWork W2398766250 @default.
- W2027837557 hasRelatedWork W2409000725 @default.
- W2027837557 hasRelatedWork W2416366082 @default.
- W2027837557 hasRelatedWork W80741246 @default.
- W2027837557 hasVolume "34" @default.
- W2027837557 isParatext "false" @default.
- W2027837557 isRetracted "false" @default.
- W2027837557 magId "2027837557" @default.
- W2027837557 workType "article" @default.